Vical Incorporated Announces Initiation Of Phase 1/2 Trial Of A Therapeutic HSV-2 Vaccine For Genital Herpes
Published: Dec 17, 2013
SAN DIEGO, Dec. 17, 2013 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the initiation of its Phase 1/2 trial of the company's Vaxfectin™-formulated therapeutic vaccine for herpes simplex virus type 2 (HSV-2), a cause of genital herpes, in approximately 156 subjects. The randomized, double-blind, placebo-controlled trial will evaluate safety, tolerability and efficacy in otherwise healthy HSV-2- infected patients aged 18 to 50 years at six key U.S. clinical sites.
Help employers find you! Check out all the jobs and post your resume.